Sacituzumab govitecan-hziy (Intravenous)
Medically reviewed by Drugs.com. Last updated on May 6, 2022.
Severe or life-threatening neutropenia may occur. Withhold sacituzumab govitecan-hziy for absolute neutrophil count below 1500/mm(3) or neutropenic fever. Monitor blood cell counts periodically during treatment during treatment. Consider G-CSF for secondary prophylaxis. Initiate anti-infective treatment in patient with febrile neutropenia without delay.Severe diarrhea may occur. Monitor patients with diarrhea and give fluid and electrolytes as needed. Administer atropine, if not contraindicated, for early diarrhea of any severity. At the onset of late diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold sacituzumab govitecan-hziy until resolved to less than or equal to Grade 1 and reduce subsequent doses .
Commonly used brand name(s)
In the U.S.
- Trodelvy
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Antineoplastic Agent
Pharmacologic Class: Sacituzumab Govitecan
Uses for sacituzumab govitecan-hziy
Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.
Sacituzumab govitecan-hziy injection is also used to treat urothelial cancer (bladder cancer and cancer of the urinary tract) that has spread or cannot be removed by surgery in patients who have received other cancer medicines (eg, immunotherapy medicine, platinum-containing cancer medicine).
Sacituzumab govitecan-hziy belongs to the group of medicines called antineoplastics (cancer medicines). It interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Some of these may be serious and must be reported to your doctor.
Sacituzumab govitecan-hziy is to be given only by or under the immediate supervision of your doctor.
Before using sacituzumab govitecan-hziy
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For sacituzumab govitecan-hziy, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to sacituzumab govitecan-hziy or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies have not been performed on the relationship of age to the effects of sacituzumab govitecan-hziy injection in the pediatric population. Safety and efficacy have not been established.
Geriatric
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of sacituzumab govitecan-hziy injection in the elderly.
Breastfeeding
There are no adequate studies in women for determining infant risk when usi..
